New Promising Therapeutic Target for Glioblastoma Identified

Research published in PNAS discovers how glioblastoma achieves invading healthy brain tissue with hardly any resistance.

Spanish researchers have discovered a new promising therapeutic target for glioblastoma.

Glioblastoma is the most frequent and aggressive brain cancer due to its ability to escape the immune system. However, the way in which this tumor manages to induce this immune tolerance was not known in detail.

Glioblastoma Multiforme | Astrocytoma Grade 4 - Types, Causes, Symptoms, Diagnosis, Treatment
Glioblastomas are tumors that arise from astrocytes that make up the supportive tissue of the brain. Glioblastomas are usually highly malignant.

‘Glioblastoma multiforme is a highly invasive cancer that is characterized by changes in cerebral blood vessels and the gradual invasion of surrounding tissues.’

A research published in PNAS carried out at the Instituto de Neurociencias UMH-CSIC, in Alicante (Spain), and the IMIB-Arrixaca in Murcia (Spain), has find out in detail how this tumor invade healthy tissue with hardly any resistance, a finding that could become glioblastoma´s Achilles heel.

The team led by Dr. Salvador Martínez, director of the UMH-CSIC Institute of Neurosciences in Alicante (Spain), and Dr. Rut Valdor, of IMIB-Arrixaca in Murcia (Spain), has shown how glioblastoma hijacks the contractile cells that surround the blood vessels of the brain and are also part of the barrier that protects it. The objective is to deactivate the antitumoral function of that these cells, called pericytes, and force them to work on the expansion of the tumor.

This change in the function of the pericytes, which are no longer defending cells to become "enemies", is achieved by glioblastoma by altering one of the cellular "cleaning services": chaperone mediated autophagy. Through autophagy the cell breaks down and destroys damaged or abnormal proteins. And chaperones are proteins that actively work on this task. The alteration by the glioblastoma of this cleaning service changes the proinflammatory defense function of the pericytes by another immunosuppressive, which favors the survival of the tumor.

New Drug Target for Glioblastoma Identified
New drug target for glioblastoma was found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.

Inactivating the tumor

Researchers have been able to verify in a mouse model that blocking this anomalous autophagy hinders the development of the tumor, causing defective adhesion of glioblastoma to the pericyte and, with it, the death of cancer cells, so it becomes a promising therapeutic goal. "This work reveals a previously unknown capacity of glioblastoma to modulate chaperone mediated autophagy (AMC) in pericytes, and thus promote tumor progression. Our results point to the AMC as a promising therapeutic goal to treat this aggressive brain cancer so far without cure", says Dr. Martínez.

Novel Targeted Therapy Against Glioblastoma
Researchers at the Spanish National Cancer Research Centre used mouse models to suppress glioblastoma tumor growth by blocking TRF1 telomere protein.

Previous this group showed that the influence of glioblastoma on the pericyte prevents destructive T lymphocytes from attacking the tumor. "That is why the brain does not detect glioblastoma and cannot react against it," explains Salvador Martínez, director of the Experimental Neurobiology group at the Instituto of Neurociencias UMH-CSIC in Alicante.

This new finding narrows the fence against this aggressive brain tumor and is in line with the current hypothesis about the role of autophagy in suppressing the early stages of tumor development and how alterations in this process contribute to its progression.

Patient Survival In Glioblastoma Depends on DNA Modifications
Study shows the distribution of a DNA defect in the glioblastoma genome and its relationship with patient survival.

It is the most frequent brain tumor with the worst prognosis. Despite decades of intense research, its complex biology is still not fully understood and existing treatments have not achieved a significant increase in survival.

Source-Eurekalert